Last checked at 3 Apr 2017 07:00
3 April 2017
Oncimmune Holdings plc
("Oncimmune" or the "Company")
GRANT OF OPTIONS AND DEALING BY PDMR
Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today announces that on 31 March 2017, options over 175,000 ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") were awarded to certain US employees, including 20,000 to Dan Calvo, President of Oncimmune (USA) LLC, a PDMR, under the Company's Oncimmune Holdings Plc Incentive Stock Option Plan (as amended from the Oncimmune Limited Incentive Stock Option Plan that became effective 27 July 2009) as follows:
Name | Position | Number of share options awarded | Option exercise price per share (pence) | Interest in issued share capital (%) |
Dan Calvo | President of Oncimmune (USA) LLC | 20,000 | 119 | 0.02 |
The options are subject to the rules of the Incentive Stock Option Plan and vest in five equal annual parts, the first fifth vesting on 30 March 2018 and each year thereafter for a further four years, subject to continued employment. The options are exercisable at 119 pence, being the mid-market closing price of the Ordinary Shares on 31 March 2017
For further information:
Oncimmune Holdings plc
Geoffrey Hamilton-Fairley, Chief Executive Officer
contact@oncimmune.co.uk
Zeus Capital Limited (Nominated Adviser and Broker)
Phil Walker, Giles Balleny, Dominic Wilson
+44 (0) 203 829 5000
Media enquiries:
Consilium Strategic Communications
Chris Gardner, Mary-Jane Elliott, Matthew Neal, Lindsey Neville
oncimmune@consilium-comms.com
+44 (0) 20 3709 5708
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name | Dan Calvo | ||||
2 | Reason for the notification | |||||
a) | Position/status | President of Oncimmune (USA) LLC, PDMR | ||||
b) | Initial notification/Amendment
| Initial Notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Oncimmune Holdings plc | ||||
b) | LEI | 213800HCYIWT6YPI1I02 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument Identification code | options over Ordinary Shares - Oncimmune Holdings Plc Incentive Stock Option Plan
ISIN GB00BYQ94H38 | ||||
b) | Nature of the transaction
| Grant of options over Ordinary Shares | ||||
c) | Price(s) and volume(s)
|
| ||||
d) | Aggregated information
|
| ||||
e) | Date of the transaction
| 31 March 2017 | ||||
f) | Place of the transaction | N/A | ||||